Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells.

Ricci-Vitiani L, Mollinari C, di Martino S, Biffoni M, Pilozzi E, Pagliuca A, de Stefano MC, Circo R, Merlo D, De Maria R, Garaci E

FASEB journal : official publication of the Federation of American Societies for Experimental Biology21 Jun 2010Cited by 29 (Europe PMC)

PMID20566622DOI10.1096/fj.10-159970PepBankPUB-20566622

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01LabEndogenous levelIn vitro (cells)Other
In colorectal cancer stem cells from different patients, Tbeta4 levels were higher than in normal epithelial cells.
In plain wordsIn lab cells, colon cancer stem cells had higher natural thymosin beta‑4 than normal epithelial cells.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTbeta4 levels in CR-CSCs versus normal epithelial cells
Study
humann: not reported in source
Colorectal cancer stem cells (CR-CSCs) from patients
Comparator
Normal epithelial cells
Outcome group
Tumor growth · Cancer
Source sentences
Summary
We first found that CR-CSCs from different patients have higher Tβ4 levels than normal epithelial cells.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2056662201

Studies that did not test the peptide alone6

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome
In mice with xenografts of colorectal cancer stem cells, Tbeta4 knockdown reduced tumor size and aggressiveness.
In plain wordsIn mice, tumors from colon cancer stem cells with lowered thymosin beta‑4 were smaller and less aggressive.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseXenograft tumor size and aggressiveness after Tbeta4 knockdown
Study
mousen: not reported in source
CR-CSC xenografts
Comparator
Empty vector-transduced CR-CSCs
Outcome group
Tumor growth · Cancer
Source sentences
Summary
reduced tumor size and aggressiveness of CR-CSC-based xenografts in mice.
2 context sentences(design, population, supporting numbers)
Summary · context
Then, we used a lentiviral strategy to down-regulate Tβ4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs.
Summary · context
Empty vector-transduced CR-CSCs were used as a control.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2056662203
03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Efficacy outcome
In colorectal cancer stem cells, lentiviral Tbeta4 knockdown lowered the capacity to grow and migrate in culture.
In plain wordsIn cells, lowering thymosin beta‑4 in colon cancer stem cells reduced their growth and migration.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseGrowth and migration of CR-CSCs after Tbeta4 knockdown
Study
humann: not reported in source
Colorectal cancer stem cells (CR-CSCs) from patients
Comparator
Empty vector-transduced CR-CSCs
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Targeting of the Tβ4 produced CR-CSCs with a lower capacity to grow and migrate in culture
2 context sentences(design, population, supporting numbers)
Summary · context
Then, we used a lentiviral strategy to down-regulate Tβ4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs.
Summary · context
Empty vector-transduced CR-CSCs were used as a control.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2056662202
04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In colorectal cancer stem cells, Tbeta4 knockdown significantly increased PTEN.
In plain wordsIn cells, lowering thymosin beta‑4 in colon cancer stem cells raised PTEN.
Peptide
Thymosin beta-4 (human)
Outcome
IncreasePTEN expression after Tbeta4 knockdown
Study
humann: not reported in source
Colorectal cancer stem cells (CR-CSCs) from patients
Comparator
Empty vector-transduced CR-CSCs
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
a significant increase of phosphatase and tensin homologue (PTEN)
2 context sentences(design, population, supporting numbers)
Summary · context
Then, we used a lentiviral strategy to down-regulate Tβ4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs.
Summary · context
Empty vector-transduced CR-CSCs were used as a control.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2056662204
05LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In colorectal cancer stem cells, Tbeta4 knockdown reduced integrin-linked kinase (ILK) expression.
In plain wordsIn cells, lowering thymosin beta‑4 in colon cancer stem cells reduced ILK.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseILK expression after Tbeta4 knockdown
Study
humann: not reported in source
Colorectal cancer stem cells (CR-CSCs) from patients
Comparator
Empty vector-transduced CR-CSCs
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
a concomitant reduction of the integrin-linked kinase (ILK) expression
2 context sentences(design, population, supporting numbers)
Summary · context
Then, we used a lentiviral strategy to down-regulate Tβ4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs.
Summary · context
Empty vector-transduced CR-CSCs were used as a control.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2056662205
06LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In colorectal cancer stem cells, Tbeta4 knockdown decreased activation of protein kinase B (Akt).
In plain wordsIn cells, lowering thymosin beta‑4 in colon cancer stem cells reduced Akt activation.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseAkt activation after Tbeta4 knockdown
Study
humann: not reported in source
Colorectal cancer stem cells (CR-CSCs) from patients
Comparator
Empty vector-transduced CR-CSCs
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
which resulted in a decreased activation of protein kinase B (Akt).
2 context sentences(design, population, supporting numbers)
Summary · context
Then, we used a lentiviral strategy to down-regulate Tβ4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs.
Summary · context
Empty vector-transduced CR-CSCs were used as a control.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2056662206
07LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism
In colorectal cancer stem cells, exogenous expression of an active form of Akt rescued all protumoral features lost after Tbeta4 knockdown.
In plain wordsIn cells, adding active Akt restored the cancer-promoting features lost when thymosin beta‑4 was lowered.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseRescue of protumoral features by active Akt after Tbeta4 knockdown
Study
humann: not reported in source
Colorectal cancer stem cells (CR-CSCs) from patients
Comparator
Empty vector-transduced CR-CSCs
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Accordingly, exogenous expression of an active form of Akt rescued all the protumoral features lost after Tβ4 targeting in CR-CSCs.
2 context sentences(design, population, supporting numbers)
Summary · context
Then, we used a lentiviral strategy to down-regulate Tβ4 expression in CR-CSCs and analyzed the effects of such modulation on proliferation, survival, and tumorigenic activity of CR-CSCs.
Summary · context
Empty vector-transduced CR-CSCs were used as a control.
In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).
Report a problemFND-2056662207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.